NCT04061824View on ClinicalTrials.gov

Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

May 24, 2016

Primary Completion Date

December 20, 2018

Study Completion Date

December 20, 2018

Conditions
HypertensionDyslipidemias
Interventions
DRUG

Olostar Tab (olmesartan/rosuvastatin FDC(fixed dose combination))

In intervention group, patients had a pill of fixed-dose combination of Olmesartan medoxomil and Rosuvastatin, rather taking separated two pills.

DRUG

Two separated drugs(ARB(Angiotensin Ⅱ receptor blocker) and statin)

In control group, patients had two separated pills for hypertension and dyslipidemia. One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin, Pravastatin, Fluvastatin and Atorvastatin/Ezetimibe).

Trial Locations (1)

Unknown

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, 50 Yonsei-ro, Seodaemun-gu, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT04061824 - Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia | Biotech Hunter | Biotech Hunter